Cancer Pain Market Size, Share Analysis and Industry Report 2024-2031

Cancer Pain Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Cancer Pain Market&nbsp;Size, Share &amp; Trends Analysis Report By Drug Class, By Application, By Route of Administration,&nbsp;By End-user, By Region, And Segment Forecasts, 2024 &ndash; 2031</h2>

<h3>Market Overview</h3>

<blockquote>
The global cancer pain market reached US$ YY&nbsp;million in 2023 and is expected to reach US$ YY&nbsp;million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
</blockquote>

The global cancer pain market designed for the pharmaceutical and medical devices sector focused on addressing pain associated with cancer. Cancer pain can arise from various factors, including the tumor pressing on nerves or organs, treatments like chemotherapy or radiation, or cancer-related procedures, Managing cancer pain is crucial for improving patients&#39; quality of life and overall well-being.

The cancer pain market is often related to different oncology disorders and is one of the major complications of cancer disorder. The nature of cancer pain primarily depends on the type of cancer, stage, and intervention such as targeted therapy and chemotherapy used in the treatment of cancer. The cancer pain initiates because of the enlargement of the tumor mass reducing bones, nerves, and other organs.

Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostics procedures, or the skin, nerve, and the other changes caused by a hormone imbalance or immune responses. Cancer pain may originate from the actual disease state or related treatments including chemotherapy, surgery, and other medicines. This pipeline of innovative treatments is helping to meet the rising demand.

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size&nbsp;
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Drug Class, Application, Route of Administration, and End-User
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&#39;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/cancer-pain-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers</h3>

The growing cancer prevalence

The global cancer pain market is driven by multiple factors. The growing number of cancer cases globally, with millions of new cases reported annually, is the key factor propelling market growth.

The global cancer pain market is a vital sector in the healthcare industry that has managed to support and diminish pain in individuals with cancer. It encloses various pharmaceutical and non-pharmaceuticals providing personalized medication for cancer patients, including analgesic treatment, home health care services, and supportive therapies.

In addition, lifestyle modifications, and an aging&nbsp;population are driving growth in the industry. Cancer is a leading cause of death worldwide. In 2023, cancer claimed a total of 9.6 to 10 million people globally. This translates to over 26,300 cancer-related deaths every day.

This increase in cancer cases would drive the demand for effective pain management solutions, thereby fueling the cancer pain market growth. According to the National Center for Health Statistics, in 2023, approximately 1,958,310 new cases and 609,820 cancer deaths are projected to occur in the U.S.

Relief from physical, psychosocial, and spiritual problems through palliative care is possible for more than 90% of patients with advanced stages of cancer. Improved access to oral morphine is strongly recommended for the treatment of moderate to severe cancer pain, suffered by over 80% of people with cancer in the terminal phase.

Moreover, key player strategies such as partnerships and collaborations would drive the market. For instance, in 2023,&nbsp;Pfizer and Seagen collaborated to reinvent cancer treatment in the future. Pfizer&#39;s determination to tackle the problems associated with cancer and enhance healthcare outcomes was demonstrated by this partnership, which aims to create cutting-edge medications and vaccines that benefit patients worldwide.

Also, in 2023, to enhance its oncology pipeline with modern cancer therapies like pelabresib and tulminetostat, Novartis partnered with Morohosys AG. This purchase demonstrates Novarti&#39;s dedication to creating cutting-edge cancer treatment solutions and is in line with the company&#39;s strategy focus on oncology.

Restraints

Factors such as various side effects associated with pain medications, opioid misuse &amp; addiction, high cost of the treatment, Lack of knowledge regarding pain assessment and management among clinicians, Unequal healthcare infrastructure and inflated healthcare expenses, stringent regulatory requirements for drug approvals, limited accessibility of cancer care management, are expected to hamper the market.

<h3>Segment Analysis</h3>

The global cancer pain market is segmented based on drug class, application, route of administration,&nbsp; end-user, and region.

The opioids segment accounted for approximately 54.4% of the&nbsp; global cancer pain market share

The opioids segment is expected to hold the largest market share over the forecast period. The opioid segment of the global cancer pain market offers a wide variety of medications catering to different pain levels and patient needs. For example, codeine or tramadol were used to treat mild to moderate cancer pain, and stronger opioids like morphine, oxycodone, or fentanyl were frequently needed to treat severe pain. By attaching to opioid receptors in the brain and spinal cord, these opioids modify how pain is perceived.

In&nbsp;2023,&nbsp;an NCBI study released, that moderate-to-severe pain is experienced by about 30.6% of cancer patients throughout their illness, and 44.5% of patients suffer pain overall. This indicates that cancer pain is a considerable burden for patients. Opioids are essential for controlling cancer pain, offering efficient relief, and enhancing the quality of life for patients.

In addition, industry major players launch innovative products helps to drive the market. For instance, in October 2022, Parker Laboratories Inc. will expand its analgesic line, introducing Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Cream to its HelixTM brand, complementing its existing range of pain relief creams and medical contact media.

Also in July 2021, Venus Remedies Limited announced the launch of a consumer healthcare division that will provide various products for cancer pain management

<h3>Geographical Analysis</h3>

North America accounted for approximately 43.2% of the global cancer pain&nbsp; market share&nbsp;

North America region is expected to hold the largest market share over the forecast period. The region&#39;s cancer pain market is driven by several factors, including the increasing incidence of cancer cases, technological developments in the healthcare sector, the accessibility of pain management medicines, and the availability of a variety of chemotherapy treatment options.

In addition, the market is characterized by precision oncology and customized medicine, with increasing investments in genomics research &amp; targeted therapy, and favorable healthcare infrastructure. Moreover, government initiatives such as Precision Medicine and Affordable Care Act, and well-organized reimbursement policies in this region support the market growth.

Moreover, 2 million Americans will receive a cancer diagnosis in 2024. An estimated 2,970 males and 310,720 women have experienced breast cancer. The second most common cancer diagnosis in Americans is prostate cancer. There were 2,99,010 recorded anticipated cases. The third most common cancer diagnosis is lung and bronchus cancer, with an estimated 2,34,580 new cases reported.&nbsp;

<h3>COVID-19 Impact Analysis</h3>

The COVID-19 pandemic significantly impacted the global cancer pain market. Those receiving cancer pain treatment during the COVID-19 epidemic had to acclimatize to several changes, including treatment plan modifications, delays, and disruptions, the absence of loved ones during in-person sessions, and altered provider communication as many appointments switched to telehealth. revealed that many patients had delays and disturbances in their care during the epidemic, which is consistent with earlier studies.&nbsp;

Even though most patients were aware of the necessity for additional safety measures, interruptions and delays made them feel more anxious and stressed.

During this time, the doctors need to be mindful of how nervous their patients are how overwhelmed they are, and how depressed they might be getting. Because on so many levels, it is just a recipe for becoming depressed, being sick with a terrible disease and being afraid of this COVID and being alone and isolated.&rdquo;

<h3>Market Segmentation</h3>

By Drug Class

<ul>
	<li>Opioids</li>
	<li>NSAIDs</li>
	<li>Morphine</li>
	<li>Non-Opioids</li>
	<li>Nerve Blockers</li>
	<li>Others</li>
</ul>

By Application

<ul>
	<li>Lung Cancer</li>
	<li>Colorectal Cancer</li>
	<li>Breast Cancer</li>
	<li>Prostate Cancer</li>
	<li>Blood Cancer</li>
	<li>Others</li>
</ul>

By Route of Administration

<ul>
	<li>Oral</li>
	<li>Parenteral</li>
	<li>Others</li>
</ul>

By End-Users

<ul>
	<li>Hospitals</li>
	<li>Homecare</li>
	<li>Specialty Clinics</li>
	<li>&nbsp;Others</li>
</ul>

By Region

<ul>
	<li>North America</li>
</ul>

<ul>
	<li>U.S.</li>
	<li>Canada</li>
	<li>Mexico</li>
</ul>

<ul>
	<li>Europe</li>
</ul>

<ul>
	<li>Germany</li>
	<li>U.K.</li>
	<li>France</li>
	<li>Spain</li>
	<li>Italy</li>
	<li>Rest of Europe</li>
</ul>

<ul>
	<li>South America</li>
</ul>

<ul>
	<li>Brazil</li>
	<li>Argentina</li>
	<li>Rest of South America</li>
</ul>

<ul>
	<li>Asia-Pacific</li>
</ul>

<ul>
	<li>China</li>
	<li>India</li>
	<li>Japan</li>
	<li>South Korea</li>
	<li>Rest of Asia-Pacific</li>
</ul>

<ul>
	<li>Middle East and Africa</li>
</ul>

<h3>Competitive Landscape</h3>

The major global players in the market include CK Life Sciences (WEX Pharmaceuticals Inc), Mundipharma International., Orexo AB, DAIICHI SANKYO COMPANY, LIMITED., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., Gr&uuml;nenthal, Galena Biopharma, Meda Pharmaceuticals among others.

<h3>Key Developments</h3>

<ul>
	<li>On February 13, 2024, Radformation, a main supplier of radiation oncology software solutions, declared its strategic partnership with Icon Group. This collaboration unites the aptitude of the two organizations to change disease care through imaginative work processes and high-level software solutions.</li>
	<li>On January 25, 2024, Quibim, an organization working on changing imaging data into significant actionable data for cancer growth and treatment responses, collaborated with Merck KGaA. The collaboration means fostering high-level imaging-based diagnostics for accurate medication.</li>
</ul>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global cancer pain market segmentation based on drug class, application, route of administration, end-user, and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development</li>
	<li>Excel data sheet with numerous data points of global cancer pain market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping is available in excel consisting of key products of all the major players.</li>
</ul>

The global cancer pain market report would provide approximately 70 tables, 71 figures, and 180 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Drug Class</li>
		<li>Snippet by Application</li>
		<li>Snippet by Route of Administration</li>
		<li>Snippet by End-User</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>The Growing Cancer Prevalence</li>
				<li>Growing Elderly Population and Unhealthy Lifestyle</li>
				<li>Rising Healthcare Expenditure And Government Support</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Side Effects Associated with Pain Medications</li>
				<li>Opioid Misuse &amp; Addiction</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
		<li>PESTEL Analysis</li>
		<li>Patent Analysis</li>
		<li>SWOT Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Drug Class</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Attractiveness Index, By Drug Class</li>
		</ol>
		</li>
		<li>Opioids*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>NSAIDs</li>
		<li>Morphine</li>
		<li>Non-Opioids</li>
		<li>Nerve Blockers</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Lung Cancer *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Colorectal Cancer</li>
		<li>Breast Cancer</li>
		<li>Prostate Cancer</li>
		<li>Blood Cancer</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Route of Administration</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Attractiveness Index, By Route of Administration</li>
		</ol>
		</li>
		<li>Oral*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Parenteral</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End-User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Attractiveness Index, By End-User</li>
		</ol>
		</li>
		<li>Hospitals *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Homecare</li>
		<li>Specialty Clinics</li>
		<li>&nbsp;Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>CK Life Sciences (WEX Pharmaceuticals Inc) *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Mundipharma International.</li>
		<li>Orexo AB</li>
		<li>DAIICHI SANKYO COMPANY, LIMITED.</li>
		<li>Hisamitsu Pharmaceutical Co., Inc.</li>
		<li>Pfizer Inc.</li>
		<li>Gr&uuml;nenthal</li>
		<li>Galena Biopharma</li>
		<li>Meda Pharmaceuticals&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Cancer Pain Market Value, By Drug Class, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Cancer Pain Market Value, By Application, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Cancer Pain Market Value, By Route of Administration, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Cancer Pain Market Value, By End-User, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Cancer Pain Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 6 Global Cancer Pain Market Value, By Drug Class, 2023, 2027 &amp; 2031 (US$ Million)

Table 7 Global Cancer Pain Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 8 Global Cancer Pain Market Value, By Application, 2023, 2027 &amp; 2031 (US$ Million)

Table 9 Global Cancer Pain Market Value, By Application, 2022-2031 (US$ Million)

Table 10 Global Cancer Pain Market Value, By Route of Administration, 2023, 2027 &amp; 2031 (US$ Million)

Table 11 Global Cancer Pain Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Cancer Pain Market Value, By End-User, 2023, 2027 &amp; 2031 (US$ Million)

Table 13 Global Cancer Pain Market Value, By End-User, 2022-2031 (US$ Million)

Table 14 Global Cancer Pain Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 15 Global Cancer Pain Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Cancer Pain Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 17 North America Cancer Pain Market Value, By Application, 2022-2031 (US$ Million)

Table 18 North America Cancer Pain Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Cancer Pain Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 North America Cancer Pain Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Cancer Pain Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 22 Asia-Pacific Cancer Pain Market Value, By Application, 2022-2031 (US$ Million)

Table 23 Asia-Pacific Cancer Pain Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 Asia-Pacific Cancer Pain Market Value, By End-User, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Cancer Pain Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Cancer Pain Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 27 Europe Cancer Pain Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Europe Cancer Pain Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Cancer Pain Market Value, By End-User, 2022-2031 (US$ Million)

Table 30 Europe Cancer Pain Market Value, By Country, 2022-2031 (US$ Million)

Table 31 South America Cancer Pain Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 32 South America Cancer Pain Market Value, By Application, 2022-2031 (US$ Million)

Table 33 South America Cancer Pain Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 South America Cancer Pain Market Value, By End-User, 2022-2031 (US$ Million)

Table 35 South America Cancer Pain Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East and Africa Cancer Pain Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 37 Middle East and Africa Cancer Pain Market Value, By Application, 2022-2031 (US$ Million)

Table 38 Middle East and Africa Cancer Pain Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East and Africa Cancer Pain Market Value, By End-User, 2022-2031 (US$ Million)

Table 40 Middle East and Africa Cancer Pain Market Value, By Country, 2022-2031 (US$ Million)

Table 41 CK Life Sciences (WEX Pharmaceuticals Inc): Overview

Table 42 CK Life Sciences (WEX Pharmaceuticals Inc): Product Portfolio

Table 43 CK Life Sciences (WEX Pharmaceuticals Inc): Key Developments

Table 44 Mundipharma International: Overview

Table 45 Mundipharma International: Product Portfolio

Table 46 Mundipharma International: Key Developments

Table 47 Orexo AB: Overview

Table 48 Orexo AB: Product Portfolio

Table 49 Orexo AB: Key Developments

Table 50 DAIICHI SANKYO COMPANY, LIMITED: Overview

Table 51 DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio

Table 52 DAIICHI SANKYO COMPANY, LIMITED: Key Developments

Table 53 Hisamitsu Pharmaceutical Co., Inc: Overview

Table 54 Hisamitsu Pharmaceutical Co., Inc: Product Portfolio

Table 55 Hisamitsu Pharmaceutical Co., Inc: Key Developments

Table 56 Pfizer Inc: Overview

Table 57 Pfizer Inc: Product Portfolio

Table 58 Pfizer Inc: Key Developments

Table 59 Gr&uuml;nenthal: Overview

Table 60 Gr&uuml;nenthal: Product Portfolio

Table 61 Gr&uuml;nenthal: Key Developments

Table 62 Teva Pharmaceutical Industries Ltd: Overview

Table 63 Teva Pharmaceutical Industries Ltd: Product Portfolio

Table 64 Teva Pharmaceutical Industries Ltd: Key Developments

Table 65 Galena Biopharma: Overview

Table 66 Galena Biopharma: Product Portfolio

Table 67 Galena Biopharma: Key Developments

Table 68 Meda Pharmaceuticals: Overview

Table 69 Meda Pharmaceuticals: Product Portfolio

Table 70 Meda Pharmaceuticals: Key Developments

List of Figures

Figure 1 Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 2 Global Cancer Pain Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 3 Global Cancer Pain Market Share, By Application, 2023 &amp; 2031 (%)

Figure 4 Global Cancer Pain Market Share, By Route of Administration, 2023 &amp; 2031 (%)

Figure 5 Global Cancer Pain Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 6 Global Cancer Pain Market Share, By Region, 2023 &amp; 2031 (%)

Figure 7 Global Cancer Pain Market Y-o-Y Growth, By Drug Class, 2023-2031 (%)

Figure 8 Opioids Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 9 NSAIDs Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 10 Morphine Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 11 Non-Opioids Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 12 Nerve Blockers Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 13 Others Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 14 Olmesartan Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 15 Telmisartan Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 16 Global Cancer Pain Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 17 Lung Cancer Application in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 18 Colorectal Cancer Application in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 19 Breast Cancer Application in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 20 Prostate Cancer Application in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 21 Blood Cancer Application in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 22 Other Application in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 23 Global Cancer Pain Market Y-o-Y Growth, By Route of Administration, 2023-2031 (%)

Figure 24 Oral Route of Administration in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 25 Parenteral Route of Administration in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 26 Others Route of Administration in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 27 Global Cancer Pain Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 28 Hospitals End-User in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 29 Homecare End-User in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 30 Specialty Clinics End-User in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 31 Others End-User in Global Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 32 Global Cancer Pain Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 33 North America Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 34 North America Cancer Pain Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 35 North America Cancer Pain Market Share, By Application, 2023 &amp; 2031 (%)

Figure 36 North America Cancer Pain Market Share, By Route of Administration, 2023 &amp; 2031 (%)

Figure 37 North America Cancer Pain Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 38 North America Cancer Pain Market Share, By Country, 2023 &amp; 2031 (%)

Figure 39 Asia-Pacific Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 40 Asia-Pacific Cancer Pain Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 41 Asia-Pacific Cancer Pain Market Share, By Application, 2023 &amp; 2031 (%)

Figure 42 Asia-Pacific Cancer Pain Market Share, By Route of Administration, 2023 &amp; 2031 (%)

Figure 43 Asia-Pacific Cancer Pain Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 44 Asia-Pacific Cancer Pain Market Share, By Country, 2023 &amp; 2031 (%)

Figure 45 Europe Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 46 Europe Cancer Pain Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 47 Europe Cancer Pain Market Share, By Application, 2023 &amp; 2031 (%)

Figure 48 Europe Cancer Pain Market Share, By Route of Administration, 2023 &amp; 2031 (%)

Figure 49 Europe Cancer Pain Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 50 Europe Cancer Pain Market Share, By Country, 2023 &amp; 2031 (%)

Figure 51 South America Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 52 South America Cancer Pain Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 53 South America Cancer Pain Market Share, By Application, 2023 &amp; 2031 (%)

Figure 54 South America Cancer Pain Market Share, By Route of Administration, 2023 &amp; 2031 (%)

Figure 55 South America Cancer Pain Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 56 South America Cancer Pain Market Share, By Country, 2023 &amp; 2031 (%)

Figure 57 Middle East and Africa Cancer Pain Market Value, 2022-2031 (US$ Million)

Figure 58 Middle East and Africa Cancer Pain Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 59 Middle East and Africa Cancer Pain Market Share, By Application, 2023 &amp; 2031 (%)

Figure 60 Middle East and Africa Cancer Pain Market Share, By Route of Administration, 2023 &amp; 2031 (%)

Figure 61 Middle East and Africa Cancer Pain Market Share, By End-User, 2023 &amp; 2031 (%)

Figure 62 CK Life Sciences (WEX Pharmaceuticals Inc): Financials

Figure 63 Mundipharma International: Financials

Figure 64 Orexo AB: Financials

Figure 65 DAIICHI SANKYO COMPANY, LIMITED: Financials

Figure 66 Hisamitsu Pharmaceutical Co., Inc: Financials

Figure 67 Pfizer Inc: Financials

Figure 68 Gr&uuml;nenthal: Financials

Figure 69 Teva Pharmaceutical Industries Ltd: Financials

Figure 70 Galena Biopharma: Financials

Figure 71 Meda Pharmaceuticals: Financials

Cancer Pain Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Colorectal Cancer Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 04

Starting from

Cancer Tumor Profiling Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 24

Starting from

Cancer Treatment Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 May 27

Starting from